Product
Allogeneic cytomegalovirus-specific T cells
1 clinical trial
3 indications
Indication
Glioblastoma MultiformeIndication
AstrocytomaIndication
Grade IVClinical trial
Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma MultiformeStatus: Recruiting, Estimated PCD: 2026-04-01